- CEO
- Dan Yin
- Full Time Employees
- 2,258
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Huanggang China
- IPO Date
- Mar 20, 2023
- Business
- Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is a China-based chemical and pharmaceutical manufacturing company founded in 2002 and headquartered in Luotian County, Hubei Province. The company specializes in the research, development, production, and sale of fine chemical raw materials, pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished pharmaceutical preparations, and new energy electrolyte materials. Operating a vertically integrated manufacturing model, the company supplies healthcare, veterinary, and battery manufacturing sectors across mainland China and international markets throughout Asia, Europe, North America, and Africa.
The company's product portfolio is organized into five primary segments: active pharmaceutical ingredients, including metronidazole, benzoyl metronidazole, dimetridazole, acyclovir, and valacyclovir hydrochloride; pharmaceutical intermediates, comprising imidazole, 2-methylimidazole, 2-methyl-5-nitroimidazole, glyoxylic acid, guanine, diacetylguanine, diacetylacyclovir, and penicillin-derivative synthesis agents; organic chemical raw materials, including glyoxal and oxalic acid; finished pharmaceutical preparations, consisting of traditional Chinese medicines and chemical pharmaceutical dosage forms such as Pudilan Xiaoyan tablets, Huoxiang Zhengqi liquid, Qingre Jiedu oral solutions, tablets, capsules, and granules across antiviral, antibacterial, anti-inflammatory, and gastrointestinal therapeutic categories; and new energy materials, featuring battery-grade lithium hexafluorophosphate (LiPF6) produced through proprietary rheological phase synthesis for lithium-ion battery electrolyte applications. The company conducts its manufacturing, research, and marketing operations through its corporate divisions and operating subsidiaries, which include Hubei Tongdetang Pharmaceutical Co., Ltd., Hubei Xinnuowei Chemical Co., Ltd., Wuhan Shuanglong Pharmaceutical Co., Ltd., Hubei Hongyuan Chemical Technology Co., Ltd., Hubei Hongyuan Fluorochemical Co., Ltd., Hubei Wanmizhai Pharmaceutical Co., Ltd., and Hubei Zhonglan Hongyuan New Energy Materials Co., Ltd.
In recent corporate developments, the company completed its initial public offering and listed its Class A shares on the ChiNext board of the Shenzhen Stock Exchange under ticker symbol 301246, raising capital to fund capacity expansions across its core chemical and advanced materials facilities. In its new energy materials segment, the company completed acceptance and commercial operation of its 2,000-ton-per-year lithium hexafluorophosphate technological upgrade project and advanced development on its 6,000-ton high-purity crystalline lithium hexafluorophosphate production facility. In addition, the company continues to execute on upstream-downstream vertical integration initiatives, expanding its production capacities for key starting materials, scaling its pharmaceutical preparation manufacturing lines, and broadening international market penetration for its core nitroimidazole and antiviral intermediate product lines.